Sirolimus-associated	sirolimus-associated	O	O
proteinuria	proteinuria	O	S_disease
and	and	O	O
renal	renal	O	O
dysfunction	dysfunction	O	O
.	.	O	O

Sirolimus	sirolimus	S_chemicals	O
is	is	O	O
a	a	O	O
novel	novel	O	O
immunosuppressant	immunosuppressant	S_chemicals	O
with	with	O	O
potent	potent	O	O
antiproliferative	antiproliferative	O	O
actions	actions	O	O
through	through	O	O
its	its	O	O
ability	ability	O	O
to	to	O	O
inhibit	inhibit	O	O
the	the	O	O
raptor-containing	raptor-containing	O	O
mammalian	mammalian	B_chemicals	O
target	target	B_chemicals	O
of	of	I_chemicals	O
rapamycin	rapamycin	S_chemicals	O
protein	protein	B_chemicals	O
kinase	kinase	S_chemicals	O
.	.	O	O

Sirolimus	sirolimus	S_chemicals	O
represents	represents	O	O
a	a	O	O
major	major	O	O
therapeutic	therapeutic	O	O
advance	advance	O	O
in	in	O	O
the	the	O	O
prevention	prevention	O	O
of	of	O	O
acute	acute	O	B_disease
renal	renal	O	I_disease
allograft	allograft	O	O
rejection	rejection	O	O
and	and	O	O
chronic	chronic	O	O
allograft	allograft	O	O
nephropathy	nephropathy	O	O
.	.	O	O

Its	its	O	O
role	role	O	O
in	in	O	O
the	the	O	O
therapy	therapy	O	O
of	of	O	O
glomerulonephritis	glomerulonephritis	O	S_disease
,	,	O	O
autoimmunity	autoimmunity	O	O
,	,	O	O
cystic	cystic	O	B_disease
renal	renal	O	B_disease
diseases	diseases	O	S_disease
and	and	O	O
renal	renal	O	B_disease
cancer	cancer	O	S_disease
is	is	O	O
under	under	O	O
investigation	investigation	O	O
.	.	O	O

Because	because	O	O
sirolimus	sirolimus	S_chemicals	O
does	does	O	O
not	not	O	O
share	share	O	O
the	the	O	O
vasomotor	vasomotor	O	O
renal	renal	O	O
adverse	adverse	O	B_disease
effects	effects	O	I_disease
exhibited	exhibited	O	O
by	by	O	O
calcineurin	calcineurin	B_chemicals	O
inhibitors	inhibitors	I_chemicals	O
,	,	O	O
it	it	O	O
has	has	O	O
been	been	O	O
designated	designated	O	O
a	a	O	O
'	'	O	O
non-nephrotoxic	non-nephrotoxic	O	O
drug	drug	S_chemicals	O
'	'	O	O
.	.	O	O

However	however	O	O
,	,	O	O
clinical	clinical	O	O
reports	reports	O	O
suggest	suggest	O	O
that	that	O	O
,	,	O	O
under	under	O	O
some	some	O	O
circumstances	circumstances	O	O
,	,	O	O
sirolimus	sirolimus	S_chemicals	O
is	is	O	O
associated	associated	O	O
with	with	O	O
proteinuria	proteinuria	O	S_disease
and	and	O	O
acute	acute	O	B_disease
renal	renal	O	I_disease
dysfunction	dysfunction	O	O
.	.	O	O

A	a	O	O
common	common	O	O
risk	risk	O	O
factor	factor	O	O
appears	appears	O	O
to	to	O	O
be	be	O	O
presence	presence	O	O
of	of	O	O
pre-existing	pre-existing	O	O
chronic	chronic	O	B_disease
renal	renal	O	I_disease
damage	damage	O	O
.	.	O	O

The	the	O	O
mechanisms	mechanisms	O	O
of	of	O	O
sirolimus-associated	sirolimus-associated	O	O
proteinuria	proteinuria	O	S_disease
are	are	O	O
multifactorial	multifactorial	O	O
and	and	O	O
may	may	O	O
be	be	O	O
due	due	O	O
to	to	O	O
an	an	O	O
increase	increase	O	O
in	in	O	O
glomerular	glomerular	O	O
capillary	capillary	O	O
pressure	pressure	O	O
following	following	O	O
calcineurin	calcineurin	B_chemicals	O
inhibitor	inhibitor	I_chemicals	O
withdrawal	withdrawal	O	O
.	.	O	O

It	it	O	O
has	has	O	O
also	also	O	O
been	been	O	O
suggested	suggested	O	O
that	that	O	O
sirolimus	sirolimus	S_chemicals	O
directly	directly	O	O
causes	causes	O	O
increased	increased	O	O
glomerular	glomerular	O	O
permeability/injury	permeability/injury	O	O
,	,	O	O
but	but	O	O
evidence	evidence	O	O
for	for	O	O
this	this	O	O
mechanism	mechanism	O	O
is	is	O	O
currently	currently	O	O
inconclusive	inconclusive	O	O
.	.	O	O

The	the	O	O
acute	acute	O	B_disease
renal	renal	O	I_disease
dysfunction	dysfunction	O	O
associated	associated	O	O
with	with	O	O
sirolimus	sirolimus	S_chemicals	O
(	(	O	O
such	such	O	O
as	as	O	O
in	in	O	O
delayed	delayed	O	B_disease
graft	graft	O	B_disease
function	function	O	I_disease
)	)	O	O
may	may	O	O
be	be	O	O
due	due	O	O
to	to	O	O
suppression	suppression	O	O
of	of	O	O
compensatory	compensatory	O	S_disease
renal	renal	O	B_disease
cell	cell	O	I_disease
proliferation	proliferation	O	O
and	and	O	O
survival/repair	survival/repair	O	O
processes	processes	O	O
.	.	O	O

Although	although	O	O
these	these	O	O
adverse	adverse	O	B_disease
effects	effects	O	I_disease
occur	occur	O	O
in	in	O	O
some	some	O	O
patients	patients	O	O
,	,	O	O
their	their	O	O
occurrence	occurrence	O	O
could	could	O	O
be	be	O	O
minimised	minimised	O	O
by	by	O	O
knowledge	knowledge	O	O
of	of	O	O
the	the	O	O
molecular	molecular	O	O
effects	effects	O	O
of	of	O	O
sirolimus	sirolimus	S_chemicals	O
on	on	O	O
the	the	O	O
kidney	kidney	O	O
,	,	O	O
the	the	O	O
use	use	O	O
of	of	O	O
sirolimus	sirolimus	S_chemicals	O
in	in	O	O
appropriate	appropriate	O	O
patient	patient	O	O
populations	populations	O	O
,	,	O	O
close	close	O	O
monitoring	monitoring	O	O
of	of	O	O
proteinuria	proteinuria	O	S_disease
and	and	O	O
renal	renal	O	O
function	function	O	O
,	,	O	O
use	use	O	O
of	of	O	O
angiotensin-converting	angiotensin-converting	B_chemicals	O
enzyme	enzyme	B_chemicals	O
inhibitors	inhibitors	I_chemicals	O
or	or	O	O
angiotensin	angiotensin	B_chemicals	O
II	ii	I_chemicals	O
receptor	receptor	B_chemicals	O
blockers	blockers	I_chemicals	O
if	if	O	O
proteinuria	proteinuria	O	S_disease
occurs	occurs	O	O
and	and	O	O
withdrawal	withdrawal	O	O
if	if	O	O
needed	needed	O	O
.	.	O	O

Further	further	O	O
long-term	long-term	O	O
analysis	analysis	O	O
of	of	O	O
renal	renal	O	O
allograft	allograft	O	O
studies	studies	O	O
using	using	O	O
sirolimus	sirolimus	S_chemicals	O
as	as	O	O
de	de	O	O
novo	novo	S_chemicals	O
immunosuppression	immunosuppression	O	O
along	along	O	O
with	with	O	O
clinical	clinical	O	O
and	and	O	O
laboratory	laboratory	O	O
studies	studies	O	O
will	will	O	O
refine	refine	O	O
these	these	O	O
issues	issues	O	O
in	in	O	O
the	the	O	O
future	future	O	O
.	.	O	O

